Clincosm LogoSign in Get a demo

Covid-19 Patients With Hypertension and/or Kidney Diseases

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05465772
Collaborator
(none)
180
Enrollment
27
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

  1. correlation between COVID-19 and Hypertension and/or kidney diseases.

  2. Assess Assess the effect of COVID-19 on patients with Hypertension and/or kidney diseases.

  3. Assess the effect of hypertension and/or kidney diseases on COVID-19 presentation.

  4. Assess the outcome of COVID-19 in patients with hypertension and/or kidney diseases

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The pandemic situation with the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from China has endangered human lives. Coronavirus disease 2019 (COVID-19) is presented with asymptomatic, mild, or severe pneumonia-like symptoms¹.SARS-CoV-2 has infected humans in all age groups, of all ethnicities, both males and females while spreading through communities at an alarming rate². COVID-19 patients with hypertension, chronic kidney disease, Diabetes, malignancies, HIV, and other comorbidities could develop a life-threatening situation. From the data have reported the characteristics of comorbidities in patients with COVID-19, hypertension was present in nearly 21%, followed by diabetes in nearly 11%, and established cardiovascular disease (CVD) in approximately 7% of patients³.

    Hypertension posed an increased risk of severe morbidity (approx. 4-fold) and death (approx. 7-fold) from COVID-19 in the presence of multiple comorbidities⁴.

    The patients with underlying kidney problems are vulnerable to developing COVID-19 infection.The disease also has had consequences on longitudinal management of patients with chronic kidney disease and end stage kidney disease.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    180 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    A Study on COVID-19 Patients With Hypertension and/or Kidney Diseases Admitted to Respiratory ICU , Assiut University Hospitals.
    Anticipated Study Start Date :
    Jul 1, 2022
    Anticipated Primary Completion Date :
    Aug 1, 2024
    Anticipated Study Completion Date :
    Oct 1, 2024

    Outcome Measures

    Primary Outcome Measures

    1. Covid-19 and Hypertension and/or kidney diseases [Baseline]

      Effect of COVID-19 on patients with Hypertension and/or kidney diseases and assess the outcome of COVID-19 in patients with hypertension and/or kidney diseases.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    Patients above 18 years old. Patients who diagnosed as COVID-19 PCR positive with hypertension and/or kidney diseases.

    Exclusion Criteria:

    Young patients below 18 years old. Patients who refused to participate in reseach

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Assiut University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Aya Abdelrhman Kotb Said, Doctor, Assiut University
    ClinicalTrials.gov Identifier:
    NCT05465772
    Other Study ID Numbers:
    • covid-19 patients
    First Posted:
    Jul 20, 2022
    Last Update Posted:
    Jul 20, 2022
    Last Verified:
    Jul 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    COVID-19
    Kidney Diseases
    Hypertension

    Study Results

    No Results Posted as of Jul 20, 2022